The radiopharmaceutical is a positron emission tomography myocardial perfusion imaging agent used in patients with known or suspected coronary artery disease, according to a Feb. 25 news release from GE Healthcare.
Flyrcado received FDA approval Sept. 27, and it is expected to be available to all U.S. cardiac positron emission tomography centers by the end of 2025, the release said.
Patients undergoing mammography preferred having their images interpreted by a radiologist before and after AI review, according to a study…
Radiologists in Maine earn the highest annual mean wage, according to data published April 2 by the Bureau of Labor…
Hawaii had the lowest rate of lumbar spine MRIs performed for lower back pain between July 1, 2022, and June…
Comments are closed.
